Search Orphan Drug Designations and Approvals
-
Generic Name: | Fixed dose combination of relatlimab and nivolumab |
---|---|
Date Designated: | 06/18/2018 |
Orphan Designation: | Treatment of gastric cancer (GC) and gastro-esophageal junction cancer (GEJ). |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Bristol-Myers Squibb Co. P. O. Box 4000 Princeton, New Jersey 08543 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-